Original Article

Years of Life Lost (YLL) due to Substance Abuse in Iran, in 2014-2017: Global Burden of Disease 2010 Method


Background: Using dexmedetomidine (Dex) as a sedative agent may benefit the clinical outcomes of post-surgery patients. We reviewed randomized controlled trials (RCTs) to assess whether use of a Dex could improve the outcomes in post-surgery critically ill adults.

Methods: We searched Medline, Embase, PubMed, and the Cochrane databases for RCTs comparing Dex with propofol or a placebo in post-operative patients, all included RCTs should be published in English before Jul 2016. Citations meeting inclusion criteria were full screened, and trial available data were abstracted independently and the Cochrane risk of bias tool was used for quality assessment.

Results: Sixteen RCTs involving 2568 patients were subjected to this meta-analysis. The use of a Dex sedative regimen was associated with a reduce delirium prevalence [odd ratio (OR):0.33, 95% confidence intervals (CI): 0.24–0.45, I2= 5%, P<0.001], a shorter the length of ICU stay [mean difference (MD): -0.60, 95%CI: -0.69 to -0.50, I2=40%, P<0.001] and the length of hospital stay [MD: -0.68, 95%CI: -1.21 to -0.16, I2=0%, P=0.01]. However, using of Dex could not shorter the duration of mechanical ventilation [MD: -10.18. 95%CI: -31.08–10.72, I2=99%, P=0.34], but could shorter the time to extubation in post-surgery patients [MD: -47.46, 95%CI: -84.63–10.67, I2=98%, P=0.01].

Conclusion: The use of a Dex sedative regimen was associated with a reduce delirium prevalence, a shorter the length of ICU and hospital stay, and a shorter time to extubation in post-surgery critical ill patients.

1. Scherbaum N, Specka M (2008). Factors in-fluencing the course of opiate addiction. Int J Methods Psychiatr Res, 17(S1):S39-44.
2. Green TC (2009). Substance abuse, HIV infec-tion, medication adherence, and mortality among a cohort of aging US veterans. 1st ed. NIAAA Publication, USA, pp.: 52-68.
3. Popova S, Rehm J, Patra J (2006). Illegal drug-attributable mortality and potential years of life lost in Canada 2002: implica-tions for prevention and policy. Contemp Drug Probl, 33(3):343-66.
4. Hayden A, Hayashi K, Dong H, Milloy MJ, et al (2014). The impact of drug use pat-terns on mortality among polysubstance users in a Canadian setting: a prospective cohort study. BMC Public Health, 14(1):1153.
5. Fischer B, Rehm J, Brissette S, et al (2005). Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health, 82(2):250-66.
6. Azhdar F, Esmaeilnasab N, Moradi G, et al (2017). Estimation of intravenous drug users’ population in Kermanshah City, west of Iran in 2016 using capture-recapture method. J Res Health Sci, 17(3):e00388.
7. Rehm J, Patra J, Popova S (2006). Alcohol‐attributable mortality and potential years of life lost in Canada 2001: implications for prevention and policy. Addiction, 101(3):373-84.
8. Moazen B, Shokoohi M, Noori A, et al (2015). Burden of drug and alcohol use disorders in Iran: findings from the Global Burden of Disease Study 2010. Arch Iran med, 18(8):480-85.
9. Gomes T, Tadrous M, Mamdani MM, et al (2018). The Burden of Opioid-Related Mortality in the United States. JAMA Netw Open, 1(2):e180217.
10. Shahbazi F, Mirtorabi D, Ghadirzadeh MR, et al (2018). Analysis of mortality rate of illicit substance abuse and its trend in five years in Iran, 2014-2018. Addict Health, 10(4), 260-68.
11. ‏Ghoreishi SM, Shahbazi F, Mirtorabi SD, et al (2017). Epidemiological study of mor-tality rate from alcohol and illicit drug abuse in Iran. J Res Health Sci, 17(4): 395.
12. Shahbazi F, Mirtorabi SD, Ghadirzadeh MR, et al (2017). Characterizing mortality from substance abuse in Iran: an epidemiologi-cal study during March 2014 to February 2015. Addict Health, 9(3):166-174.
13. Shahbazi F, Mirtorabi SD, Ghadirzadeh MR, et al (2018). Epidemiological Study of Mortality from drug Abuse in Bodies Re-ferred to Iranian Legal Medicine Organi-zation in 2013-2014. Iranian Journal of Epi-demiology, 14(1):9-18.
14. Murray CJ, Ezzati M, Flaxman AD, et al (2012). GBD 2010: design, definitions, and metrics. The Lancet, 380(9859): 2063-2066.
15. Degenhardt L, Whiteford HA, Ferrari AJ, et al (2013). Global burden of disease at-tributable to illicit drug use and depend-ence: findings from the Global Burden of Disease Study 2010. Lancet, 382(9904):1564-74.
16. Scott K, Wells J, Angermeyer M, et al (2010). Gender and the relationship between marital status and first onset of mood, anxiety and substance use disor-ders. Psychol Med, 40(9): 1495-505.‏
17. Baheiraei A, Hamzehgardeshi Z, Moham-madi MR, et al (2013). Alcohol and drug use prevalence and factors associated with the experience of alcohol use in Ira-nian adolescents. Iran Red Crescent Med J, 15(3):212-217.
18. Statistical Center of Iran (2018). Population of the country in terms of gender in ur-ban and rural areas by province. Statistical Center of Iran, the Iran. Available from: www.amar.org.ir
IssueVol 49 No 11 (2020) QRcode
SectionOriginal Article(s)
DOI https://doi.org/10.18502/ijph.v49i11.4735
Dexmedetomidine Sedation Mechanical ventilation Delirium

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
SHAHBAZI F, MIRTORABI D, GHADIRZADEH MR, SHOJAEI A, HASHEMI NAZARI SS. Years of Life Lost (YLL) due to Substance Abuse in Iran, in 2014-2017: Global Burden of Disease 2010 Method. Iran J Public Health. 49(11):2170-2178.